

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 54270

**Title:** Intravascular lymphoma with hypopituitarism: A case report

**Reviewer's code:** 03251421

**Position:** Editor-in-Chief

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2020-01-20

**Reviewer chosen by:** Ruo-Yu Ma

**Reviewer accepted review:** 2020-02-25 13:43

**Reviewer performed review:** 2020-03-02 08:46

**Review time:** 5 Days and 19 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

The authors presented a well-organized case report with sufficient medical records. However, in the part of OUTCOME AND FOLLOW-UP, a brief supplement of the endocrinological condition may make the case more complete. In addition, in the part of CONCLUSION, “earlier disease stage” was mentioned in the manuscript, but what is defined as “earlier”? Is the definition of "earlier" based on the IVL severity or pituitary damage?

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 54270

**Title:** Intravascular lymphoma with hypopituitarism: A case report

**Reviewer's code:** 03548820

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Doctor, Senior Scientist

**Reviewer's Country/Territory:** Russia

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2020-01-20

**Reviewer chosen by:** Jie Wang

**Reviewer accepted review:** 2020-03-12 10:45

**Reviewer performed review:** 2020-03-13 15:19

**Review time:** 1 Day and 4 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The authors present an interesting case of intravascular lymphoma (IVL) with pituitary damage. However, significant revision of the manuscript is required: 1) Although IVL is B-cell in most cases, cases of T- and NK-cell intravascular lymphomas have also been described. The authors do not give the results of an immunohistochemical study, which is necessary, especially since the patient was treated with rituximab. 2) The authors correctly emphasize the importance of random skin biopsy for the diagnosis of IVL. Histological examination of the bone marrow is performed. Trephine biopsy of bone marrow can also indicate IVL. Here, were there any histological signs of bone marrow lesion IVL? 3) Biochemical data are lacking. Was there an increase in LDH? 4) Hemophagocytic lymphohistiocytosis (HLH) diagnosis requires a complex of diagnostic criteria [Filipovich and Chandrakasan, *Hematol Oncol Clin N Am* 29 (2015) 895-902]. Despite hemophagocytosis in bone marrow, fever and cytopenia in the patient, this is not enough to diagnose HLH.